Mitochondrial DNA Release-STING Axis as Senolytic Efficacy Predictor

The mitochondrial DNA (mtDNA) release-STING axis represents a metabolic biomarker system that leverages mitochondrial dysfunction as the primary driver of senescence detection and therapeutic targeting. This mechanism centers on the observation that senescent cells exhibit profound mitochondrial network fragmentation, oxidative damage, and membrane permeabilization that precedes nuclear chromatin instability. During senescence initiation, mitochondrial quality control mechanisms become overwhelmed, leading to the release of oxidized mtDNA fragments into the cytoplasm through compromised mitochondrial membranes and defective mitophagy. These cytoplasmic mtDNA fragments, which retain CpG-rich sequences and oxidative modifications, serve as potent activators of the cGAS-STING pathway with superior kinetics compared to nuclear-derived chromatin fragments. The temporal advantage stems from mitochondrial vulnerability to oxidative stress and metabolic disruption occurring within hours of senescence-inducing stimuli, compared to the days required for nuclear envelope deterioration.

The mitochondrial DNA (mtDNA) release-STING axis represents a metabolic biomarker system that leverages mitochondrial dysfunction as the primary driver of senescence detection and therapeutic targeting. This mechanism centers on the observation that senescent cells exhibit profound mitochondrial network fragmentation, oxidative damage, and membrane permeabilization that precedes nuclear chromatin instability. During senescence initiation, mitochondrial quality control mechanisms become overwhelmed, leading to the release of oxidized mtDNA fragments into the cytoplasm through compromised mitochondrial membranes and defective mitophagy. These cytoplasmic mtDNA fragments, which retain CpG-rich sequences and oxidative modifications, serve as potent activators of the cGAS-STING pathway with superior kinetics compared to nuclear-derived chromatin fragments. The temporal advantage stems from mitochondrial vulnerability to oxidative stress and metabolic disruption occurring within hours of senescence-inducing stimuli, compared to the days required for nuclear envelope deterioration. Cytoplasmic mtDNA recognition by cGAS occurs with 10-fold higher efficiency due to the hypomethylated state and oxidative modifications that enhance cGAS binding affinity. This creates a rapid-response inflammatory cascade through STING activation, TBK1 phosphorylation, and IRF3 nuclear translocation, establishing the senescence-associated secretory phenotype (SASP) within 6-12 hours rather than 2-3 days. The mitochondrial origin of the danger signal also correlates directly with cellular metabolic capacity and ATP availability, providing a dual readout of senescence burden and residual cellular viability. Preclinical studies using flow cytometry-based detection of cytoplasmic mtDNA combined with STING phosphorylation status demonstrate superior prediction of senolytic drug efficacy across dasatinib, quercetin, and BCL-2 family inhibitors, with 85% correlation between baseline mtDNA-STING axis activation and subsequent senolytic response magnitude.